Stool transplant plus nivolumab for advanced solid cancers
Part of Cancer clinical trials.
This study tests whether transferring stool microbiome (“FMT,” stool transplant) along with nivolumab can improve outcomes in people with advanced solid cancers that kept worsening even after anti–PD-1/PD-L1 treatment. It also looks at stool and blood changes to understand why the treatment might work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 19 years or older and have a confirmed solid cancer diagnosis
- Your cancer must have been treated with anti–PD-1 or anti–PD-L1, and the standard options are no longer working
- You must have at least one measurable tumor spot on recent scans within 28 days
- You must be well enough for study treatment (ECOG 0–2) and expected to live at least 3 months
- Your recent blood tests must be within required ranges, and you must not have had G-CSF in the prior 7 days
- Be willing to give blood and stool samples and (if you have accessible tumors) do a fresh tumor biopsy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether changes in gut bacteria can help predict how well immunotherapy works for solid cancers. It also tests whether stool (fecal microbiota) from certain immunotherapy-responding people can improve outcomes for others who are not responding well.
This trial tests whether a fecal transplant (a stool donation from a healthy person) can help patients with advanced stomach cancer respond better to treatment. If you qualify, you would receive the transplant through a colonoscopy, possibly along with other standard therapies.
This trial tests whether a fecal microbiota transplant (FMT) — transferring healthy bacteria from a donor's stool into your gut — combined with the immunotherapy drug tislelizumab can help treat advanced non-small cell lung cancer (NSCLC) that has progressed after prior treatments. It aims to see if this combination can improve outcomes by boosting your immune system's response.
This trial studies whether giving a fecal microbiota transplant (a stool-based sample from a carefully screened donor) alongside immune checkpoint inhibitors can improve outcomes in people with lung cancer. It aims to change the gut bacteria to help the immune system work better against the cancer.
This trial studies fecal microbiota transplantation (a stool-based treatment) to improve symptoms and safety in people with certain gut and immune conditions. It aims to see whether changing gut bacteria can help you feel better.
This early-phase study tests whether stool/fecal microbiota transplant (a fecal transplant) can help people who develop significant diarrhea or colitis after immune-checkpoint therapy. It aims to reduce bowel inflammation and improve symptoms, while carefully checking for infections.
Hear when a new Solid Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.